Apple Ordered to Pay $634 Million to Masimo in Landmark Apple Watch Patent Trial

In a high‑stakes intellectual‑property showdown, a federal jury in San Jose has awarded medical‑technology company Masimo a $634 million verdict against Apple Inc. The decision centers on alleged infringement of Masimo’s pulse‑oximetry patents used in the Apple Watch’s health‑monitoring features.

Background of the Dispute

Masimo, a leader in non‑invasive monitoring technologies, sued Apple in 2022, claiming that the Apple Watch’s SpO₂ sensor and related algorithms violated several of its patents covering optical sensor design and signal‑processing methods. Apple maintained that its technology was developed independently and that the patents were either invalid or not applicable to its devices.

The Jury’s Verdict

After a three‑week trial, the jury concluded that Apple did indeed infringe Masimo’s patents and found the infringement to be willful. The panel awarded $634 million in damages, one of the largest patent‑infringement verdicts ever recorded in the consumer‑electronics sector. The award includes both compensatory damages and a punitive component intended to deter future violations.

Implications for Apple

The verdict could have far‑reaching consequences for Apple’s product roadmap. Analysts note that the company may need to redesign its health‑sensor hardware or negotiate a licensing agreement with Masimo to avoid further litigation. The financial impact, while sizable, is unlikely to threaten Apple’s overall profitability, but it does highlight the growing importance of health‑tech features in wearable devices.

Industry Reaction

Industry observers see the case as a bellwether for the broader battle over wearable health technology. As more smartphones and smartwatches incorporate medical‑grade sensors, patent portfolios like Masimo’s are becoming valuable defensive assets. The ruling underscores the need for tech firms to conduct thorough freedom‑to‑operate analyses before launching health‑focused products.

Next Steps

Apple has indicated that it will appeal the decision, arguing that the jury’s findings are legally flawed. Both parties are expected to engage in post‑verdict motions, which could extend the dispute for months or even years. In the meantime, Masimo is poised to leverage the verdict to strengthen its licensing strategy and expand its presence in the consumer‑wearable market.

Conclusion

The $634 million judgment marks a pivotal moment in the intersection of consumer electronics and medical technology. Whether the case leads to a licensing settlement, a redesign of Apple’s health sensors, or a broader shift in how companies protect and monetize health‑related patents, it will undoubtedly shape the future of wearable health monitoring.

Source: Reuters, Daily Journal, Yahoo Finance.